Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 8/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | MLNR | O43193 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677492 | 1.00 | LMNA (0.52) | LMNAATMSMN1; SMN2HTR7CXCR4 | |
| SCHEMBL7097403 | 0.84 | HTR7 (0.62) | LMNAHTR7CXCR4MLNRSIGMAR1 | |
| SCHEMBL30616744 | 0.84 | HTR7 (0.64) | LMNAHTR7CXCR4MLNRSIGMAR1 | |
| SCHEMBL2472212 | 0.84 | HTR7 (0.64) | LMNAHTR7CXCR4MLNRSIGMAR1 | |
| SCHEMBL1111791 | 0.83 | ATM (0.50) | ATMSMN1; SMN2HTR7HRH3GAA | |
| SCHEMBL32667521 | 0.81 | HTR7 (0.57) | LMNAHTR7CXCR4MLNRSIGMAR1 | |
| SCHEMBL1138323 | 0.81 | HTR7 (0.57) | LMNAHTR7CXCR4MLNRSIGMAR1 | |
| SCHEMBL7098277 | 0.81 | LMNA (0.53) | LMNAHTR7CXCR4MLNRSIGMAR1 | |
| SCHEMBL7101510 | 0.81 | LMNA (0.53) | LMNAHTR7CXCR4MLNRSIGMAR1 | |
| SCHEMBL376781 | 0.81 | HTR7 (0.56) | LMNAHTR7CXCR4MLNRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | LMNA 325/4885ATM 2318/4885SMN1; SMN2 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.